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Abstract
This research is aimed to evaluate the suitability of Squacquerone cheese to support the
viability of Lactobacillus crispatus BC4, a vaginal strain endowed with a strong antimicrobial
activity against urogenital pathogens and foodborne microorganisms, in order to recom-
mend a gender food for woman wellbeing. The viability of L. crispatus BC4, used as adjunct
culture, was evaluated during the refrigerated storage of Squacquerone cheese, as well as
when the cheese was subjected to simulated stomach-duodenum passage tested by the
patented Simulator of the Human Intestinal Microbial Ecosystem (SHIME). Moreover, the
effects of L. crispatus BC4 addition were evaluated on product hydrolytic patterns, in terms
of proteolysis, lipolysis and volatile molecule profiles. The data showed that L. crispatus
BC4 maintained high viability, also in presence of physiological stress conditions, until the
end of the refrigerated storage. Moreover, the inclusion of L. crispatus BC4 gave rise to
cheese product with higher score of overall acceptability when compared to control cheese.
In addition, the survival of L. crispatus BC4, carried in test cheese, in gastro intestinal condi-
tions was confirmed by SHIME. The results showed that the vaginal Lactobacillus strain
was more affected by the low pH of the stomach, simulated by the SHIME reactor, rather
than to bile salts and pancreatic juices. Although only in vivo trials will be able to confirm the
functionality of the cheese in the vaginal environment, these data represent a first step
towards the employment of the Squacquerone cheese as probiotic food able to promote the
woman’s health by preventing gynaecological infections.
Introduction
The demand of the consumers in food production has considerably changed throughout the
years. In this time, foods can be perceived not only to satisfy hunger but also to directly con-
tribute to consumer’s health providing necessary nutrients, and preventing nutrition-related
diseases and improving the general human well-being [1]. In this framework, one of the fastest
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growing areas in the global food industry is represented by functional foods [2] considered as
dietary strategy to reduce the incidence of illness for humans. The European Commission’s
Concerted Action on Functional Food Science in Europe, coordinated by the International
Life Science Institute, described functional foods as “products having beneficial effects on one or
more functions of the human organism thus either improving the general and physical conditions
or/and decreasing the risk of the evolution of diseases. The amount and form of the functional
food should be for dietary purposes. Therefore, it could not be in pill or capsule but as food form”.
Many functional foods are characterized by health promoting features because they are vehicle
of probiotic microorganisms, which are recognized as able to provide beneficial effects to the
host, positively affecting the intestinal microflora balance, reducing the growth of pathogens,
producing and increasing the bioavailability of nutrients, favouring good digestion, decreasing
the effect of allergens, stimulating the human immune system, lowering cholesterol, alleviating
lactose intolerance, and increasing infection resistance [3–6]. The rationale for the use of pro-
biotics, independently on the vehicle used for their intake, relies mainly on their regulatory
role in modulating the gastrointestinal and genitourinary microbiota [7]. Substantial amount
of emerging research is indicating that the microbiota has a significant impact on human
health [8–15]. According to some updated papers, humans can be regarded as “holobionts” or
communities made of the host and their symbiotic microbes, rather than individuals, since the
microbiome has a fundamental role in human physiology. Indeed, the interaction between
host genome and microbiome increases the genetic variation and phenotypic plasticity, thus
enabling the holobiont to improve its general health [16–18]. Current exciting papers are
beginning to underline how foods, with their components and microbial communities and
probiotics, modulate the human symbiotic microbes [19,20].
Indeed, due to many physiological gender differences (including the physiological
responses to many pathologies), diet and probiotic foods are expected to differently influence
the male and female health though the modulation of their symbiotic microbes [18]. Until the
last decade, research on women has been ignored and the results coming from men were
directly turned to women in several medical fields [21]. However, some studies and random-
ized controlled trials devoted to the female gender, demonstrated the capability of probiotics,
used as oral or vaginal supplements, to recover from glycemic disorder in healthy pregnant
women, infectious mastitis, bacterial and Candida genitourinary infections [7, 22–24]. More-
over, some literature data showed the suitability of functional foods to prevent heart disease in
post-menopausal ages, improve the woman skin health, and positively affect the gut and vagina
microbiota of HIV positive women [25–28].
Reproductive-age women are often subjected to abnormalities in vaginal microbiota, lead-
ing to gynaecological infections, such as vulvovaginal candidiasis, bacterial vaginosis, aerobic
vaginitis and sexually transmitted diseases [29]. These disturbances interfere with female
reproductive health, promoting abortion, preterm delivery, premature rupture of membranes
and chorioamnionitis. The literature data have shown that treatments based on conventional
approaches were not successful in the handling of these disorders, and that the use of probiot-
ics can be effective in restoring the normal vaginal microbiota dominated by lactobacilli [30].
Recent studies highlighted the anti-microbial activities of Lactobacillus strains isolated from
vagina of healthy women and their potential appliance for the production of probiotic formu-
lations [31, 32]. In particular, some Lactobacillus crispatus, Lactobacillus gasseri and Lactobacil-
lus vaginalis strains were found to be active towards vaginal Candida isolates, common
urogenital pathogens and the sexually transmitted agents Chlamydia trachomatis, Neisseria
gonorrhoeae and HIV [33–36]. Those strains were also characterised for some functional and
technological properties [36] in order to evaluate their potential inclusion in dairy products.
Several strains of L. crispatus showed a significant antagonistic activity against spoilage and
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pathogenic microorganisms of food interest, their fermentation kinetics in milk and their abil-
ity to survive at 4˚C suggested their potential use as adjunct cultures for the production of
female gender foods. In this view, the production of a functional gender food based on L. cris-
patus represents a new strategy to vehicle a health-promoting strain to the vaginal environ-
ment. This idea is supported by the already demonstrated ability of probiotic strains to pass
from intestine to vagina [37–41]. In this scenario, the main aim of this research was the evalua-
tion of the suitability of a soft cheese like Squaquerone to serve as a carrier of L. crispatus BC4,
a selected vaginal strain gifted of interesting antimicrobial and technological properties
[31,36]. The effects of the inclusion of this Lactobacillus strain on the cheese safety, shelf-life,
proteolytic and lipolytic patterns, volatile molecule and sensory profiles were evaluated, and
compared to the traditional product. In addition, the viability of this strain during refrigerated
storage, simulated gastro-duodenum passage and in the patented simulator of the Human
Intestinal Microbial Ecosystem (SHIME) was evaluated since the ability to survive through the
gastrointestinal tract is notoriously fundamental for the strain functionalities in the host.
About this, SHIME system has been used as for the accurate simulation in vitro on the ability
of probiotic bacteria to merge into the intestinal environment [42]
Materials and methods
L. crispatus and cheese starter culture conditions
L. crispatus BC4, a vaginal isolate able to contrast Candida spp. and other pathogens of the uro-
genital tract [31,33,36], was used in this study for the production of a test cheese. Overnight
cultures (37˚C for 16 h) of L. crispatus were obtained in de Man-Rogosa-Sharpe (MRS) broth
(Oxoid, Basingstoke, UK) in anaerobic condition by using Oxoid gas generating kit. Cells were
harvested by centrifugation at 8,000 × g for 20 min at 4˚C. The resultant pellet was washed
twice with saline solution (0.9% NaCl in distilled water) and resuspended in commercial milk
for the inoculums in industrial environment. A commercial freeze-dried culture of Streptococ-
cus thermophilus St 0.20 (Sacco S.R.L., Como, Italy) was used as starter for Squacquerone
cheese production. The culture was inoculated in milk in the optimal conditions and in the
proportions indicated by the producer.
Squacquerone cheesemaking
The production of the Squacquerone cheeses (test cheese supplemented with L. crispatus BC4
and control cheese) was carried out in a pilot-scale plant of a local dairy farm (Mambelli, Berti-
noro, Italy) For each cheese type, 100 liters of milk were heated and maintained at 42˚C and
inoculated with the commercial starter culture of S. thermophilus (final concentration: 6 log
CFU/mL). To obtain test Squacquerone cheese, L. crispatus BC4 was added (final concentra-
tion: 6.8 log CFU/mL). After 40 minutes, the two batches were added of NaCl (0.7%) and 37
mL of rennet (12000 U, 80% chymosin and 20% pepsin, Bellucci Modena, Italy). Twenty min
after coagulation, the curd was cut and transferred into traditional moulds. The cheeses were
let to rest until the reaching of pH 5.15 and stored at 4˚C. After 1 day, the cheeses were packed
in modified atmosphere and stored at 4˚C for 18 days.
Microbiological analyses, pH and water activity
The test cheese supplemented with L. crispatus BC4 and the control cheese (without L. crispa-
tus BC4) were subjected to microbiological, pH and water activity analyses. For the microbio-
logical analyses, 20 grams of cheese was placed into 180 mL sodium citrate sterile solution (20
g/L) and homogenised in a stomacher (Lab-blender 80, Pbi International, Milan, Italy) for 3
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min. Decimal dilutions were performed in Ringer’s solution (NaCl 0.9%), and 0.1 mL of
appropriate dilutions was spread onto different agar media. S. thermophilus was counted on
M17 agar (Oxoid, Basingstoke, Hampshire, UK) (42˚C, 48 h), Lactobacillus spp. were detected
on MRS agar (37˚C, 48 h, anaerobic conditions) and the presence of L. crispatus was assured
also by checking the bacterial colony morphology. To confirm its presence, genomic DNA was
extracted from each L. crispatus presumptive colony using the InstaGene Matrix kit (Bio-Rad
Laboratories, Milano,Italy) and by sequencing the 16S rRNA region according to the protocol
described by De Angelis et al. [43]. Enterobacteriaceae and yeasts were also counted on
VRBGA (Oxoid, Basingstoke, Hampshire, UK) (37˚C, 24 h) and YPD (Oxoid, Basingstoke,
Hampshire, UK) (25˚C, 48 h) plates, respectively. The presence of pathogenic species such as
L. monocytogenes, S. enteritidis and E. coli was checked in both the cheeses during their refrig-
erated storage, according to the ISO methods 11290, 6579, and 16649, respectively.
pH and water activity were measured by diluting 10 g of cheese with 10 mL of distilled
water. pH was registered by using a pH-meter Hanna Instruments 8519 (Incofar, Modena,
Italy). Water activity (Aw) was measured by using an Aqualab Series 4TE (Decagon Device,
Inc. Pullman,WA, USA).
Proteolysis, lipolysis, volatile profiles
The test cheese supplemented with L. crispatus BC4 and the control cheese (without L. crispatus
BC4) were subjected to proteolysis, lipolysis and volatile profile. The proteolysis of the two
cheese types was monitored by SDS-PAGE. The soluble proteins at pH 4.6 were extracted from
the supernatants of the two cheese types following the method proposed by Kuchroo and Fox
[44] while the running conditions adopted are in accordance to Tofalo et al. [45]. The extraction
of cheese lipids and the determination of free fatty acid (FFA) concentrations were performed
as described by Vannini et al. [46]. The main volatile compounds were monitored by using a
GC/MS/SPME technique according to the method proposed by Burns et al. [47]. The com-
pounds were identified by use of available mass spectra databases (NIST version 2005).
Textural profile analyses
The test cheese supplemented with L. crispatus BC4 and the control cheese (without L. crispa-
tus BC4) were subjected to textural analysis over the refrigerated storage. Texture analyses
were performed after 1, 4, 6, 8 and 13 days of refrigerated storage using a Texture Analyser TA
DHI (Stable MicroSystem, Godalming, UK) and according to the method proposed by Patri-
gnani et al. [2].
Organoleptic evaluation
The test cheese supplemented with L. crispatus BC4 and the control cheese (without L. crispa-
tus BC4) were subjected to sensory evaluation over the refrigerated storage. The sensory evalu-
ation was performed throughout a panel test after 4 and 13 days of storage at 4˚C. Twenty-five
trained panellists were enrolled within the employees of Mambelli (Bertinoro, Italy) local dairy
farm (5 panellists) and of the Department of Agricultural and Food Sciences, University of
Bologna, Campus Food Science, Cesena, Italy (20 panellists). The Campus of Food Science,
where the test was organized, is provided by sensory-laboratories certified according to
regional requirements. The panellists were verbally informed on the cheese product manufac-
ture and the strains used in the research by the committee organizing the test. The committee
was formed by Dr. Patrignani, Dr. Siroli and Prof. Lanciotti. The panellists, after oral consent
to perform the test, tasted 20 g of each sample served at 15˚C under controlled conditions
according to Standard 8589 (ISO, 1988), as suggested by Gallardo-Escamilla et al. [48]. The
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assessors evaluated cheese colour, flavour, creaminess, off-flavours, bitter and overall accep-
tance attributing a score ranging from 0 (low or poor) to 5 (high or very excellent).
Evaluation of the fate of Lactobacilli population (mainly represented by L.
crispatus BC4) by Simulated stomach duodenum passage and the Simulator
of the human intestinal microbial ecosystem (SHIME)
The fate of L. crispatus BC4 was performed by the simulation of the passage through stomach
and duodenum, developed according to the method proposed by Vinderola et al.[49]. Briefly,
25 g of tested cheese was mixed with the same volume of a ‘saliva-gastric’ solution. Saliva-gas-
tric solution contained CaCl2 (0.22 g/L), NaCl (16.2 g/L), KCl (2.2 g/L), NaHCO3 (1.2 g/L) and
0.3% (w/v) porcine pepsin. Porcine pepsins from two different and undisclosed manufacturers
were used on a g/mL basis because no information about the enzymatic units was available on
the label of the products. A 1 mL sample was removed for cell counts immediately after admix-
ture and pH was quickly brought to 3.00, 2.70 or 2.50, with 5 M and 0.1 M HCl. Samples were
brought to 37˚C in a water bath. Aliquots (1 mL) were taken at the time fixed by the method
and serial dilutions were plated for cell viability assessment.
The destiny of the vaginal strain L. crispatus BC4 during passage in the human upper gas-
trointestinal tract when delivered within a cheese matrix was evaluated also in an adapted
SHIME system [50]. This system, composed of a reactor used in a sequential setup to simulate
over time first the stomach and then the small intestinal environment, has been used as for the
accurate simulation in vitro on the ability of probiotic bacteria to merge into the intestinal
environment [42].
Appropriate retention time and pH were chosen in order to resemble in vivo conditions in
the different parts of the gastrointestinal tract in fed state. Control and test cheeses were incu-
bated as reported below to simulate gastric and upper intestinal phases, both working in fed
state. 2.5 g of each cheese were used in the simulation, all experiments were conducted in trip-
licate to account for biological variability. Along the simulation, the following samples were
collected: time 0, end of stomach, small intestine after 1, 2 and 3h. Viability of the L. crispatus
strain was evaluated by means of conventional culturing techniques using selective medium
(MRS). To confirm its presence, the procedure previously described was used [43]. The
SHIME consists of a succession of reactors simulating the different parts of the human gastro-
intestinal tract. In this research, the SHIME reactor simulates over time, firstly the stomach
and then the small intestine. The applied conditions used in the simulator are summarized
below:
Gastric phase (fed state): the cheese matrix was incubated at 37˚C for 2 h at the SHIME pat-
ent conditions [50], while mixing via stirring, with sigmoidal decrease of the pH profile. Pepsin
was supplied with the activity being standardized by measuring absorbance increase at 280nm
of TCA-soluble products upon digestion of hemoglobin (reference protein). Phosphatidylcho-
line was added and followed by the addition of SHIME complex nutritional medium. The salt
(NaCl and KCl) levels were implemented according to Mackie et al. [51].
Small intestinal phase (fed state): The small intestine phase was characterized by an incuba-
tion of the cheese matrix, after gastric phase, at 37˚C for 3 h, while mixing via stirring. In this
step, pH increased to 7.4. Pancreatic enzymes, in a specific and defined ratio, were used
according to the patent. 10 mM bovine bile extract was supplemented.
Statistical analysis
The data are expressed as the mean of three repetitions and two independent experiments.
Microbiological, chemico-physical and texture data were analyzed using Statistica software
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(version 8.0; StatSoft, Tulsa, Oklahoma, USA). Means were compared using ANOVA followed
by LSD test at p< 0.05 level to mark differences between samples with the same storage times.
The volatile molecule profiles were analyzed using ANOVA followed by a principal compo-
nent analysis (PCA) performed by Statistica software.
Results
Microbiological analyses
Test Squacquerone cheeses were produced in the pilot-scale plant of a local Italian cheese-
maker using L. crispatus BC4 strain as adjunct culture with the starter one of S. thermophilus.
The test cheeses were compared to the control ones, produced in the same conditions with the
starter culture alone. The cell loads of the starter (S. thermophilus) and of Lactobacillus popula-
tion were monitored during the refrigerated storage (13 days) and reported in Fig 1, respec-
tively. The results highlighted the constant presence of S. thermophilus over the whole storage
period, independently on the presence of the adjunct culture. Notably, the inclusion of L. cris-
patus BC4 in the cheese positively affected the starter culture viability over the storage. In fact,
in the test cheese, the initial count (1d) of S. thermophilus was 7.4 log CFU/g and decreased to
5.9 log CFU/g at the end of the storage (13d), while in the control one, S. thermophilus had an
initial cell load of 6.1 log CFU/mL and it reduced to 5.0 log CFU/g (Fig 1A). Fig 1B reports the
cell loads of Lactobacillus population over the storage period. The levels of lactobacilli in the
control cheese increased from 2.1 log CFU/g (1d) to 5.0 log CFU/g (13d). By contrast, lactoba-
cilli cell load was quite constant in the test cheese and always over 7.0 log CFU/g. According to
the morphological and molecular analysis, the most abundant Lactobacillus population was
represented by L. crispatus BC4, that was inoculated at a level of 6.8 log CFU/g. On the con-
trary, L. crispatus was not found among the Lactobacillus population detected in the control
cheese. No contamination by yeasts, Enterobacteriaceae and pathogenic species was found.
Physico-chemical analyses
The pH and water activity values of Squacquerone cheeses, in relation to storage time and L.
crispatus BC4 presence, are reported in Table 1. During the storage, the pH decreased both in
test and control cheese, even if, at the end of the storage, the pH of the cheese containing L.
crispatus BC4 was lower than the control. Regarding water activity, the two cheese types pre-
sented significant different values at the beginning of the shelf-life while after 13 d of storage
no significant difference was recorded between the two cheese types.
Cheese ripening profiles
The proteolytic profiles of the two types of Squacquerone cheese, containing or not L. crispatus
BC4, are represented in the heat map reported in Fig 2. The dendrogram of the cheese proteins
soluble at pH 4.6 showed similar weight molecular bands for the two cheese types up to 6 days
of storage. As the storage time increased, significant differences between the test and control
cheeses were detected. In fact, after 13 days of refrigerated storage, the cheese containing L.
crispatus BC4 showed a proteolytic profile very similar to that of the control cheese after 8 days
of storage, with the exception of the band corresponding to 66 KDa. This protein band, corre-
sponding to the molecular weight of bovine serum albumin, characterized the test cheese
while it was absent in the control cheese, suggesting that the activity of the adjunct culture
affected the matrix protein network and the whey separation and, consequently, the retention
of whey proteins. This hypothesis is also corroborated by the rheological data showing that
cheese containing L. crispatus BC4 was characterized by a significantly higher creaminess, with
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Fig 1. Evolution of Streptococcus thermophilus (a) and Lactobacillus population (b) concentrations in test and control Squacquerone cheese during
the refrigerated storage (1, 4, 6, 8, 11, 13 days). Cell loads are expressed as mean Log CFU/g cheese ± standard deviation. Control and test cheese cell
loads were statistically compared at each sampling time. Comparing the same day of sampling, cell loads values of test and control cheeses having
different symbols are significant different (p <0.05).
https://doi.org/10.1371/journal.pone.0208906.g001
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PLOS ONE | https://doi.org/10.1371/journal.pone.0208906 January 9, 2019 7 / 19
respect to the control cheese, also immediately after cheesemaking. Also the faster decrease of
the pH during storage in test cheese probably contributed to modify the water binding capacity
of the proteins and their interaction with the other macromolecules of the system. In fact, the
pH has a key role in the interaction between proteins and other macromolecules [52]. By con-
trast, the low molecular weight bands differed between the two cheese typologies only for their
abundance (Row-Z-score). More specifically, peptides having molecular weights ranging
between 21.07 and 14.18 KDa were more abundant in the control cheese.
The cheese FFA contents recorded between 4 and 13 days of storage at 4˚C, are shown in
Table 2. After 4 days of storage, the control cheese presented FFA profiles characterized by
C12:0, C14:0, C16:0, and C18:1, while the test cheese was characterized by C10:0, C14:0, C16:0,
C18:0 and C18:1.Over the storage, in both cheese typologies the release of FFA increased, even
though with different trends in relation to the presence of L. crispatus. The C18:0 was detected
in the control cheese after 6 days of storage. Branched anteiso 17 carbon atoms, as well as
long-chain fatty acids such as C18:2 and C20:0 appeared in test cheese type between 6 and 13
days of storage. Both in the control and in the test cheese, also 15 carbon atom FFAs and C18:2
appeared after 6 days of storage. However, the presence of L. crispatus BC4 fastened the release
of FFAs, whose concentrations peaked at 8 days of storage, and then decreased probably due
to their further transformation in aroma compounds. By contrast, in control cheese the accu-
mulation of the reported FFAs continued over time and peaked at the end of storage.
The volatile molecule profiles of the two types of Squacquerone cheese were monitored
over the refrigerated storage using the GC/MS/SPME technique. The detected molecules
belonged to different classes of compounds such as alcohols, esters, acids and ketones. To eval-
uate the consequences of the inclusion of L. crispatus BC4 over time, the detected volatile com-
pounds were analysed using a principal component analysis (PCA). In Fig 3, the projection of
samples and detected molecules is reported. The PCA was able to explain over 60% of the total
variance among the samples over time. All the test cheese samples, independently on the time
of storage, clustered together, with the exception of the test cheese after 13 days of storage that
was very similar to the control one at the same time of storage. At 1, 4 and 6 days of storage,
the test cheese was principally characterized by ketones and alcohols, while the control cheese
was characterized by ketones, short fatty acids and esters. At the end of the shelf-life, 2-buta-
none, propanone and, at minor amount, ethanol were found in both types of cheese.
Table 1. Evolution of pH and water activity in test and control cheese over refrigerated storage.
Storage (d) pH aw
Test cheese 1 5.35 ± 0.01a 0.987±0.001a
4 5.45 ± 0.02 a 0.991±0.001a
6 5.38 ± 0.01a 0.992±0.001a
8 5.35 ± 0.01a 0.993±0.001a
13 5.10 ± 0.01a 0.991±0.001a
Control cheese 1 5.29 ± 0.02b 0.972±0.001b
4 5.27 ±0.01 b 0.991±0.002a
6 5.28 ± 0.03b 0.998±0.001b
8 5.28 ±0.02b 0.997±0.001b
13 5.22 ± 0.03b 0.992±0.001a
At each sampling time, pH and water activity values of test and control cheeses were statistically compared.
Comparing the same day of sampling, physic-chemical values of control and test cheeses having different capital
letters (a or b) were significant different (p<0.05).
https://doi.org/10.1371/journal.pone.0208906.t001
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Fig 2. Heat-map relative to the proteolitic patterns detected in control and test Squacquerone cheeses in relation to the refrigerated storage time
(4, 6, 8, 13 days). Protein molecular weight: A1: 78.39 KDa; A2: 66.00 KDa; A3: 51.56 KDa; A4: 25.22 KDa; A5: 23.92 KDa; A6: 21.07 KDa; A7: 19.57
KDa; A8: 17.81 KDa; A9: 15.14 KDa; A10: 14.18 KDa.
https://doi.org/10.1371/journal.pone.0208906.g002
Table 2. Free fatty acids (ppm ± standard deviation) detected in the two types of Squacquerone cheese in relation to the storage time.
Test cheese Control cheese
4d 6d 8d 13d 4d 6d 8d 13d
(C10:0) Decanoic acid, methyl ester 2.2±0.1 2.2±0.2 - 3.6±0.3 - - - 3.0±0.2
(C12:0) Methyl dodecanoate -� 3.1±0.3 2.5±0.1 5.4±0.2 2.7±0.2 2.2±0.1 2.8±0.2 3.3±0.1
(C14:0) Methyl tetradecanoate 4.4±0.5 10.2±0.5 11.7±0.4 20.0±1.1 7.3±0.2 8.2±0.2 9.8±0.4 10.8±0.1
(C15:0) Methyl pentadecanoate - - 2.7±0.2 3.8±0.3 - 2.1±0.1 2.6±0.1 2.6±0.2
(C16:1) Methyl cis-9-hexadecenoate - - - 2.6±0.2 - - - -
(C16:0) Methyl hexadecanoate 44.0±1.5 89.1±2.1 122.7±2.9 224.4±3.0 68.4±0.9 96.6±2.3 109.6±2.2 127.4±11
(a-17:0) Methyl 14-methylhexadecanoate - - 2.2±0.1 - - - - -
(C17:0) Methyl heptadecanoate - 2.1±0.1 2.3±0.1 3.5±0.2 - - 2.1±0.1 2.3±0.1
(C18:2) Methyl cis-9,12-octadecadienoate - - 2.1±0.1 2.9±0.1 - - 2.1±0.1 3.6±0.2
(C18:1) Methyl cis-9-octadecenoate 5.2±1.0 7.6±0.3 19.8±1.3 18.9±0.2 6.0±0.3 6.2±0.1 10.7±1.0 12.2±1.2
(C18:1) Methyl trans-9-octadecenoate - - 2.5±0.1 - - - - -
(C18:0) Methyl octadecanoate 44.6±1.8 89.7±2.4 134.3±3.4 103.4±1.9 - 80.2±2.6 98.3±1.4 134.2±3.1
(C20:0) Methyl eicosanoate - - 2.4±0.3 2.2±0.1 - - - 2.1±0.1
TOTAL FFA 100.4±4.6a 204.0±5.9a 305.2±8.9a 290.7±7.3a 84.4±1.8b 195.5±5.3a 238.0±7.2b 301.5±6.2a
�under the detection limit
At each sampling time, total FFA values of test and control cheeses were statistically compared. Comparing the same day of sampling, total FFA values of control and
test cheeses having different capital letters (a or b) were significant different (p<0.05).
https://doi.org/10.1371/journal.pone.0208906.t002
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Panel test
The sensory analysis was performed on the two types of cheese after 4 and 13 days of storage
and showed that test cheese was preferred compared to the control (Fig 4). In fact, after 4 days,
test cheese received a significant higher score compared to the control cheese for the overall
acceptance. This positive evaluation was principally affected by sensory features such as cream-
iness, flavour, and lacking of off-flavours, balancing the low scores received for the colour attri-
bute. After 13 days of storage, the sensory differences perceived by the panellists were
significantly reduced, although the test cheese still remained more appreciated than the control
for all the parameters considered.
Textural profile
The textural analyses of hardness and consistency over refrigerated storage is reported in Fig 5,
respectively. Regarding hardness, significant differences between the two types of Squacquer-
one cheese were assessed for any storage time considered (1–13 days). Consistency was found
significantly different between the two cheese products up to 8 days of refrigerated storage.
Evaluation of the fate of test cheese Lactobacilli population (mainly
represented by L. crispatus BC4) in simulated stomach-duodenum passage
and in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
A simulation of the passage of the test cheese through stomach and duodenum was carried
out, and the surviving levels of Lactobacilli (mainly represented by L. crispatus BC4) were eval-
uated. The presence of L. crispatus was verified by genomic DNA extraction from colonies and
sequencing the 16S rRNA region according to the method previously indicated.
At 4 and 13 days of refrigerated storage, test cheese were subjected to different chemical
stresses. The simulated physiological stresses applied on the test cheese after 4 days of storage
showed that L. crispatus BC4 (added in the test cheese at level of 7 log CFU/g) was more
affected by the application of gastric stress conditions than the duodedum stress. In fact, when
gastric condition was applied to the test cheese, containing Lb. crispatus BC4, after 4 days of
storage, its Lactobacilli cell load values decreased of 1 log cycle (Fig 6). When the test cheese
after 13 days of storage was subjected to the stomach duodenum passage, the viability of Lacto-
bacilli population were more affected by the application of intestinal juice stress.
Results related to the survival of the Lactobacillus population in the upper gastro intestinal
tract under simulated fed conditions in SHIME are shown in Fig 7, which reports the plate
count cell loads of lactobacilli detected before and after the exposure to stomach condition,
and 1, 2 and 3 hours after the exposure to the small intestine conditions.
Plate count data on MRS medium showed that the transit in the stomach led to a decrease
of approx. 3 Log units in lactobacilli viability in the test cheese. During transition in the small
intestine, Lactobacillus population levels remained constant in the test cheese. The presence of
L. crispatus, at the highest cell loads, was verified by genomic DNA extraction and sequencing
the 16S rRNA region according to the method previously indicated. These data showed that
the vaginal strain was initially significant affected by the low pH in the stomach while it was
resistant to bile salts and pancreatic juices.
Fig 3. Plot of cases (a) and variables (b) obtained by PCA elaboration of the total volatile molecules characterising control and
test Squacquerone cheeses in relation to the refrigerated storage time (1, 4, 6, 13 days). CC1: control cheese after 1 day of
storage; CC4: control cheese after 4 days of storage; CC6: control cheese after 6 days of storage; CC13: control cheese after 13
days of storage; PC1: Test cheese after 1 day of storage; PC4: Test cheese after 4 days of storage; PC6: Test cheese after 6 days of
storage; PC13: Test cheese after 13 days of storage.
https://doi.org/10.1371/journal.pone.0208906.g003
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Discussion
The present research is part of a wider project aimed to use food as strategy to increase woman
well-being. Generally, since vaginal dysbiosis and other gynaecological infections are generally
characterised by a reduction in vaginal lactobacilli content, the administration of probiotics,
Fig 4. Spider web chart of the sensory data of control and test Squacquerone cheeses after 4 (a) and 13 (b) days of refrigerated storage. The sensory
evaluation of the samples, assessed by a trained assessment panel, considered cheese colour, flavour, creaminess, off-flavours, bitter and overall
acceptance attributing a score ranging from 0 (poor) to 5 (very excellent).
https://doi.org/10.1371/journal.pone.0208906.g004
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especially lactobacilli, has been proposed as a valid treatment for vaginal disorders. In fact, a
wide literature reports that the administration of probiotics is able to restore the normal vagi-
nal microbiota [53–56]. Beside the vaginal application, a wide literature shows that probiotic
bacteria can be administered orally, also through foods, due to their ability to pass from the
intestine to the vagina, with a consequent beneficial impact on the vaginal habitat [37–41].
Fig 5. Textural analyses of hardness (a) and consistency (b) evaluated in control and test Squacquerone cheeses during
the refrigerated storage (1, 4, 6, 8, 13 days). Results are expressed as mean ± standard deviation. For the statistical
analysis, control and test cheeses were compared at each sampling time. Comparing the same day of sampling, textural
values of control and test cheeses having different capital letters were significant different (p<0.05).
https://doi.org/10.1371/journal.pone.0208906.g005
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Among probiotic bacteria, L. crispatus, being routinely found in the vagina of healthy women,
is considered one of the most active species in maintaining the eubiosis [30,31,57–59] and sev-
eral pharmaceutical preparations based on selected strains of L. crispatus has been proposed
and sometimes patented [32,60].
As an alternative to pharmaceutical or nutraceutical preparations, the present research
aimed to develop a probiotic soft cheese as dietary strategy to increase woman wellbeing and
particularly to prevent or solve dysbiosis disorders.
In this framework the results of the present study show that Squacquerone cheese can rep-
resent a suitable carrier of L. crispatus, able to preserve the strain viability during the refriger-
ated storage and the simulated gastro intestinal digestion, respecting the hedonistic features of
foods. In fact, L. crispatus BC4 maintained levels of about 7 log CFU/g up to 13 days of refrig-
erated storage. These cell loads allow a daily intake of 100 g of cheese to introduce the probiotic
cell amount recommended by FIL-IDF (International Dairy Federation) that, depending on
the probiotic strain, range between 8 and 12 log CFU/day. Consequently, the strain herein
considered, fulfills two of the main criteria to select probiotic microorganisms to be included
in food systems: i) the compatibility with eventual starter culture during cheese making and ii)
the maintenance of cell loads of at least 6 log CFU/g throughout the shelf life [61,62]. In addi-
tion, the Squacquerone cheese matrix resulted able to assure the protection of the L. crispatus
against the simulated physiological stresses (low pH, high bile salt concentration, presence of
digestive enzymes) characterizing the digestion process. In fact, at the end of the simulated
stomach-duodenum passage, the strain showed a viability higher of 6 log CFU/g, indepen-
dently on the storage time considered. Soft cheeses like Squacquerone or Crescenza are consid-
ered optimal carrier and dietary strategy to transfer probiotic strains as they are characterised
by a protective protein and fat matrix, neutral or sub-alkaline pH, and high buffering capacity,
Fig 6. Evolution of Lactobacillus population cell loads in test Squacquerone cheese at 4 and 13 days of refrigerated storage, subjected to
simulated stomach-duodenum passage. Cell loads are expressed as mean Log CFU/g cheese ± standard deviation. The cell load values recorded after
4 days of cheese refrigeration was statistically compared in relation to the stress applied. Values significant different are highlighted with different
superscript letter (p<0.05). The cell load values recorded after 13 days of cheese refrigeration was statistically compared in relation to the stress
applied. Values significant different are highlighted with different superscript letter (p<0.05).
https://doi.org/10.1371/journal.pone.0208906.g006
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properties able to protect the probiotic bacteria during their gastro-intestinal transit
[47,62,63]. In addition, these cheeses can represent a good source of calcium and vitamins,
particularly important for the woman wellbeing. The test cheese containing L. crispatus BC4
was also subjected to the Simulator of the Human Intestinal Microbial Ecosystem (SHIME).
These reactors simulated, over time, firstly the stomach and then the small intestine under fed
conditions. Differently from the simulated stomach duodenum passage, the incubation condi-
tions and timing are optimized in the SHIME system in order to resemble in vivo situation in
the different regions of the gastrointestinal tract. The data obtained confirmed the viability of
L. crispatus BC4, to survive to the in vivo stress that the strain can encounter during the diges-
tion process, evidencing its higher sensitiveness toward gastric conditions with respect to bile
salts and pancreatic juice.
Notably, the inclusion of the L. crispatus BC4 improved the organoleptic properties of the
cheese in terms of creaminess, flavour and overall acceptance. This is an important feature
since the probiotic products are often characterized by lack of good sensory properties and sev-
eral strategies were proposed to overcome such probiotic food drawbacks [64,65]. In fact, L.
crispatus BC4 strain affected, although at levels compatible with the short ripening time, both
the proteolytic and lipolytic patterns of cheese and, consequently, the volatile molecule pro-
files. These modifications resulted in a product appreciated by the panellists involved in the
sensory analysis.
Fig 7. Evolution of Lactobacillus population cell loads in test Squacquerone cheese subjected to the Simulator of the Human Intestinal Microbial
Ecosystem (SHIME). Plate counts were carried out before (ST0) and after (STend) the stomach condition exposure, and after 1 (SI1), 2 (SI2) and 3 (SI3)
h of exposure to the small intestine conditions. Cell loads are expressed as mean Log CFU/mL cheese ± standard deviation. Cell loads values having
different symbol are significant different for Lactobacilli population cell loads (p<0.05).
https://doi.org/10.1371/journal.pone.0208906.g007
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Conclusions
Although only in vivo clinical trials can definitely confirm the functional properties of a food,
these data represent the first important tassel in the use of the Squacquerone cheese, contain-
ing L. crispatus BC4, as dietary strategy for woman well-being. The novelty of this work con-
sists in the use of a Lactobacillus species, exclusively associated with the vaginal habitat and
recognized as healthy marker, for the production of a probiotic food that can promote the
woman’s health by preventing gynaecological infections. At present the use of L. crispatus has
been reported only in pharmaceutical formulations; for this reason, our work is a pioneer in
the proposal of using this health-promoting vaginal species in the preparation of functional
foods of gender.
However, next step of this research will include clinical studies to verify the potential of this
functional cheese in humans to prevent vaginal diseases.
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